Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Regeneron Pharmaceuticals Inc (REGN) vs Weibo Corp (WB) Price & Performance

Regeneron Pharmaceuticals IncTrade
Weibo CorpTrade

Price performance (Past 24H)

Key statistics

Regeneron Pharmaceuticals Inc vs Weibo Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Weibo Corp trades at $6.64 (market cap $1.64B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 50.9× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.11%). Which is the better fit depends on your goals.

REGNWB
Market Cap
$83.43B$1.64B
Sector
HealthMedia
52-Week High
$852.03$12.83
52-Week Low
$555.51$6.63
Enterprise Value
$78.14B$866.57M
Dividend Yield
0.46%9.11%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Weibo Corp

Weibo (WB) trades at $6.70, down 0.3% on the day, with mixed technical signals showing bearish moving averages but bullish oscillators. Fundamentally, the stock appears undervalued with a P/E of 5.53 and P/B of 0.41, while maintaining strong profitability with 73.36% gross margins and 17.78% net income margin. Recent Q2 2026 earnings beat expectations with $0.38 EPS versus $0.36 expected, though Q1 and Q4 2025 missed estimates.

The investment case balances deep value metrics against structural challenges. While the stock trades below book value and generates substantial cash flow, competitive pressures from Douyin and WeChat threaten long-term relevance. Analyst sentiment is divided with 41% buy ratings but 45% holds, reflecting uncertainty about growth visibility amid declining user metrics. The 8% dividend yield provides downside protection but may not offset fundamental erosion risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN

About Weibo Corp

Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.

Read more on WB